Exiqon Diagnostics, Inc. Announces BRAF Mutation Analysis for Predicting Therapeutic Response in Colorectal Cancer Patients

VEDBAEK, Denmark, July 8, 2009 (GLOBE NEWSWIRE) -- Exiqon announced today that it now offers BRAF Mutation Analysis through its CLIA laboratory in California. Cancer treating physicians now have access to this critical test for their advanced stage colorectal cancer patients who are candidates for anti-EGFR targeted therapy. A recent clinical study correlates the presence of BRAF mutations in colorectal cancer tumors with lack of patient response to cetuximab and panitumumab therapy.(1)